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ABSTRACT 
Annual influenza vaccination is strongly recommended for patients with chronic pulmonary 
diseases, such as bronchial asthma, chronic obstructive pulmonary disease (COPD), and inter-
stitial pulmonary diseases. However, many of these patients regularly receive systemic and/or 
inhaled corticosteroid therapy, and the impact of corticosteroid therapy on influenza vaccine 
efficacy and safety is unclear. Patients with chronic pulmonary diseases were enrolled in the 
study and divided into three groups based on their maintenance therapy: (A) without cortico-
steroid therapy (17 males, three females; mean age, 72.3 ± 7.9), (B) oral corticosteroid thera-
py (four males, seven females; mean age, 66.1 ± 10.6), and (C) inhaled corticosteroid therapy 
(eight males, nine females; mean age, 62.4 ± 16.0). All patients received influenza vaccine, 
and serum hemagglutination inhibition (HI) antibodies against influenza strains A/H1N1, 
A/H3N2, and B were measured at baseline (before vaccination) and 4-6 weeks after vaccina-
tion. Sufficient antibody titers or significant increases were observed after vaccination com-
pared with titers before vaccination in all three groups. No systemic reactions were reported. 
Long-term oral/inhaled corticosteroid therapy was not associated with vaccination side effects 
and did not affect the immune response to the influenza vaccine. 
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INTRODUCTION 
Influenza is a major public health prob-
lem that causes significant morbidity and 
mortality worldwide (Lambert and Fauci, 
2010; Igarashi et al., 2011). Yearly vaccina-
tion prevents influenza-related complica-
tions and reduces influenza prevalence 
(Nichol et al., 2007). Elderly patients with 
chronic pulmonary diseases such as bron-
chial asthma, chronic obstructive pulmo-
nary disease (COPD), and interstitial pul-
monary diseases are strongly recommended 
to receive an annual influenza vaccine to 
prevent disease symptom exacerbation or 
loss of pulmonary function due to respirato-
ry tract infection (Nichol et al., 2007; Inoue 
et al., 2003, 2009). However, many patients 
with chronic pulmonary diseases regularly 
receive systemic or inhaled corticosteroid, 
and it is well known that systemic cortico-
steroid administration restrains immune re-
sponses, such as antibody production (Bax-
ter and Harris, 1975). Despite this, few 
studies have investigated the influence of 
steroid therapy on influenza vaccine effica-
cy and safety, and the effects of regular oral 
or inhaled corticosteroids on these parame-
EXCLI Journal 2013;12:760-765 – ISSN 1611-2156 
Received: April 25, 2013, accepted: August 23, 2013, published: August 29, 2013 
 
761 
ters were unclear. In this study, we evaluat-
ed the efficacy and safety of the influenza 
vaccine in elderly patients with chronic 
pulmonary diseases who were receiving 
oral or inhaled corticosteroids. 
 
MATERIALS AND METHODS 
Patient characteristics 
This prospective study was carried out 
between October 2004 and April 2005. A 
total of 48 patients with chronic respiratory 
diseases, with or without oral or inhaled 
corticosteroid treatment, were recruited 
from Yamaguta University Hospital and 
enrolled in the study (those who received 
both oral and inhaled corticosteroid were 
excluded). The patients were classified into 
three groups based on their maintenance 
therapy: (A) without corticosteroid therapy 
(17 males, three females; mean age, 72.3 ± 
7.9), (B) oral corticosteroid therapy (four 
males, seven females, mean age, 66.1 ± 
10.6; median corticosteroid dose: 10.0 mg/ 
day (2.5–25 mg/day), equivalent to predni-
solone), or (C) inhaled corticosteroid thera-
py (eight males, nine females; mean age, 
62.4 ± 16.0; median inhaled corticosteroid 
dose: 800 μg/day (400–1600 μg/day), equi-
valent to budesonide). All patients with 
chronic respiratory diseases were stable be-
fore receiving vaccination. Patient charac-
teristics are summarized in Table 1. 
 
Study protocol 
All patients received a single subcuta-
neous inoculation of the trivalent influenza 
vaccine from the same lot containing he-
magglutinin of influenza HA1 (A/Beijing), 
HA2 (A/Taiwan), and HB (B/Panama), 
from Mitsubishi Tanabe Pharma Co. Osaka, 
Japan. Blood samples were collected to 
measure antibody titers against influenza A 
and B antigens before vaccination and 4-6 
weeks after vaccination. 
Serum antibody titers were measured 
with hemagglutination inhibition (HI) as-
says. The serum samples were serially di-
luted and co-incubated with influenza anti-
gen and 0.5 % chicken red blood cells. The 
HI titter was determined as the reciprocal of 
the highest serum dilution resulting in non-
agglutination of red blood cells. Vaccina-
tion efficacy was evaluated by seroconver-
sion, defined as a pre-vaccination HI titer < 
1:10 and a post-vaccination HI titer ≥ 1:40 
or a pre-vaccination HI titer ≥ 1:10 and a 
minimum four-fold rise in post-vaccination 
HI antibody titer and seroprotection, de-
fined as a post-vaccination HI titer of 
≥ 1:40 (Chotirosniramit et al., 2012). 
 
 
 
Table 1: Patients' profiles 
  A B C 
n 20 11 17 
Male/female 17/3 4/7 8/9 
Mean age, years old (mean ± SD) 72.3 ± 7.9 66.1 ± 10.6 62.4 ± 16.0 
    
Chronic obstructive pulmonary disease 12 0 1 
Bronchial asthma 1 0 16 
Interstitial pneumoia 1 8 0 
Diffuse panbronchitis 3 0 0 
Bronchiectasis 2 0 0 
Sarcoidosis 0 2 0 
Aftereffects of pulmonary tuberculosis 1 0 0 
Lung cancer 0 1 0 
A: Control patients; B: patients treated by systemic corticosteroid;  
C: patients treated by inhaled corticosteroid 
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Statistical analysis 
Data are shown as mean ± standard de-
viation (SD). Pre- and post-vaccination HI 
titers were compared with paired t tests. 
Possible influences of oral or inhaled ster-
oid therapy were evaluated with Chi-
squared tests. 
 
RESULTS 
Serum antibody responses against influ-
enza vaccine antigens were increased from 
baseline values in all three groups (Fig-
ure 1). In group A, we observed significant 
increases in HA1 and HA2 titers. Although 
there was no significant difference in HB 
antibody HI titer between pre- and post-
vaccination, HB antibody HI titers were 
sufficient for seroprotection. Group B ex-
hibited significant increases in HI titers for 
HA2 and HB. Although there was no sig-
nificant difference in HA1 antibody HI titer 
between the two time points, the HI titers 
were high enough for seroprotection. In 
group C, significant increases in HI titers 
against HA1 and HB were noted. Although 
we did not observe a significant difference 
in HA2 antibody HI titer levels between 
pre- and post-vaccination, the levels were 
high enough to confer seroprotection.  
Vaccination effectiveness findings are 
summarized in Table 2. In patients who re-
ceived inhaled corticosteroid therapy, the 
ratio of seroconversion or seroprotection for 
HB was significantly higher than in patients 
without corticosteroid therapy. A local re-
action was observed at the injection site 
within several days after vaccination in one 
patient, but no systemic reactions were ob-
served. 
 
DISCUSSION 
We investigated the efficacy and safety 
of the influenza vaccine in elderly patients 
with chronic pulmonary diseases receiving 
oral or inhaled corticosteroid therapy. 
Maintenance treatment with oral or inhaled 
corticosteroid therapy in this population did 
not reduce the serological response to influ-
enza vaccination. In fact, Table 2 shows 
that the serological response to HB was 
significantly reduced in patients without 
corticosteroid therapy. Overall, nine of 20 
control patients (without corticosteroid 
therapy) did not show a serological re-
sponse after vaccination. Our findings sug-
gest that inhaled corticosteroid did not exert 
a significant immunosuppressive effect. 
In patients with chronic pulmonary dis-
ease, respiratory tract infection is the most 
prevalent cause of acute symptom exacer-
bation (Inoue et al., 2003, 2009). This is 
especially true in COPD patients; respirato-
ry tract infections due to influenza virus or 
rhinovirus induce secondary bacterial infec-
tion and severe respiratory failure (Igarashi 
et al., 2011; McManus et al., 2008). Pa-
tients with chronic pulmonary diseases are 
strongly urged to receive an annual influen-
za vaccination, and many of them also re-
ceive oral and/or inhaled corticosteroid 
treatment. We did not find any significant 
 
Table 2: The ratio of seroconversion or seroprotection after vaccination 
 Ratios p values 
seroconversion  
or seroprotection 
A 
control 
B 
oral CS 
C 
inhaled 
CS 
A vs B A vs C B vs C 
HA1 19/20 10/11 16/17 0,6573 0,9058 0.7475 
HA2 20/20 10/11 17/17 0,1705 ND 0.2055 
HB 9/20 6/11 14/17 0.6109 0.0196 0.1117 
Numbers are those responding (seroconversion or seroprotection) / total vaccinated. Response ratios 
are evaluated by the Chi-square test. CS: corticosteroid. ND: p value for control vs inhaled corticoster-
oid was not caluculated because all subjects were positive for seroconversion or seroprotection 
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Figure 1: Pre- and post-vaccination antibody titers against HA1, HA2, and HB. Group A, patients 
without corticosteroid therapy; Group B, patients with oral corticosteroid therapy; and Group C, pa-
tients with inhaled corticosteroid therapy 
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differences in antibody production against 
influenza strains between patients with or 
without corticosteroid therapy. A few stud-
ies have investigated the influence of corti-
costeroids on influenza vaccine-induced 
antibody production (Kubiet et al., 1996; 
Hanania et al., 2004), but ours is the first 
report that shows effective antibody pro-
duction against influenza in elderly patients 
with chronic pulmonary diseases who were 
receiving oral or inhaled corticosteroid.  
It is well known that long-term systemic 
corticosteroid therapy is immunosuppres-
sive (Lipworth, 1999). Indeed, we found 
that pre-vaccination antibody titers were 
lower in patients treated with oral or in-
haled corticosteroid compared to patients 
without steroid therapy. Despite this obser-
vation, there were no significant post-
vaccination differences between the groups. 
These results suggest that vaccinating pa-
tients with chronic pulmonary diseases who 
receive corticosteroid treatment against in-
fluenza is effective. 
There are some limitations in our study. 
First, it was performed at a single center, so 
the number of subjects enrolled was not 
large. Second, the dose of systemic steroid 
was relatively low in this study population, 
so the effects of high-dose corticosteroid 
treatment on antibody production against 
influenza is still unknown. Third, only one 
patient treated with inhaled corticosteroid 
was infected with influenza A, and one pa-
tient without corticosteroid therapy was in-
fected with influenza B during the study 
period. As such, we could not investigate 
any potential preventative effect of the cor-
ticosteroid treatment on influenza infection. 
Fourth, most patients had received the flu 
vaccine for multiple consecutive years, and 
many exhibited high antibody titers before 
vaccination; therefore, we cannot ignore the 
influence of previous vaccinations on anti-
body titer levels. 
In conclusion, influenza vaccination is 
safe and effectively stimulates antibody 
production even in patients treated with oral 
or inhaled corticosteroid. Further investiga-
tion in a much larger population will be 
necessary to confirm our results.  
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